Effectiveness of COVID-19 Vaccines Against Hospitalization and Severe Disease in Children with Diabetes Mellitus During Pandemic and Post-Pandemic Eras
Authors:
- Laura G. CoelhoLCLaura G. Coelho
- Lilian M. DinizLDLilian M. Diniz
- Stella C. GalanteSGStella C. Galante
- Cristiane S. DiasCDCristiane S. Dias
- Maria Christina L. OliveiraMOMaria Christina L. Oliveira
- Enrico A. ColosimoECEnrico A. Colosimo
- Ana Cristina Simões e SilvaASAna Cristina Simões e Silva
- Fernanda N. DuelisFDFernanda N. Duelis
- Maria Eduarda T. BernardesMBMaria Eduarda T. Bernardes
- Daniela R. MartelliDMDaniela R. Martelli
- Fabrício Emanuel S. OliveiraFOFabrício Emanuel S. Oliveira
- Hercílio Martelli-JuniorHMHercílio Martelli-Junior
Open Access
- 20 February 2026
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 501
Abstract
Pediatric patients with SARS-CoV-2 infection are at an increased risk of severe disease and adverse outcomes. Nevertheless, comprehensive data on COVID-19 vaccine effectiveness (VE) in children with diabetes during the post-pandemic period remain limited. This study assessed the VE against severe COVID-19 outcomes during both the pandemic and post-pandemic phases in children with and without diabetes mellitus (DM). A cohort study based on population data was carried out, including all patients under 18 years of age with symptomatic SARS-CoV-2 infection as registered in the Brazilian national surveillance systems from February 2020 to June 2025. The main outcomes were hospitalization due to COVID-19 and severe illness, which included admission to the intensive care unit (ICU), need for invasive ventilation, and death. Utilizing a propensity score-matched cohort, we estimated the VE and the number needed to vaccinate (NNV) for a booster dose against these outcomes by comparing vaccinated and unvaccinated individuals, employing conditional logistic regression adjusted for confounding variables. The cohort comprised 3,730,007 pediatric patients with COVID-19, of whom 7675 (0.2%) had DM. At baseline, children with DM exhibited a significantly higher prevalence of hospitalization (11.2% vs. 2.0%), severe COVID-19 (6.4% vs. 0.6%), and mortality (1.9% vs. 0.1%) than those without DM (all p < 0.001). During the pandemic period, the adjusted VE was consistently higher in children with DM. Against severe disease, the VE was 72.8% (95% CI: 12.3–93.2) in the DM cohort compared with 45.7% (28.1–59.0) in the non-DM cohort. This increased effectiveness corresponded to a more favorable NNV; the NNV to prevent one severe case was 24 (95% CI: 12–232) for children with DM versus 243 (168–440) for those without DM. In the post-pandemic period, the VE remained significantly higher in the DM cohort. Against severe disease, the VE was 76.2% (11.5–93.5) for children with DM and 52.9% (32.7–67.1) for those without. The NNV to prevent one severe case was consistently lower in the DM cohort (8 vs. 591). In conclusion, a complete vaccination regimen, including a booster dose, substantially mitigated severe COVID-19 outcomes in children with DM in the pandemic and post-pandemic periods.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (405731/2023-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (301522/2025-1)
- FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-03205-24)
- FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-04839-24)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 45 references indexed in Scilit:
- A Population-Based Epidemiologic Study of Symptomatic SARS-CoV-2 Infections and Fatalities in Brazilian Children over 3 YearsThe Journal of Pediatrics, 2024
- SARS-CoV-2 vaccination in children and adolescents with and without type 1 diabetes mellitusEndocrine, 2023
- New‐onset type 1 diabetes in children and adolescents as postacute sequelae of SARS‐CoV‐2 infection: A systematic review and meta‐analysis of cohort studiesJournal of Medical Virology, 2023
- From emergency response to long-term management: the many faces of the endemic state of COVID-19The Lancet Regional Health - Europe, 2023
- Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysisDiabetologia, 2023
- Vaccine Effectiveness against SARS-CoV-2 Variants in Adolescents from 15 to 90 Days after Second Dose: A Population-Based Test-Negative Case-Control StudyThe Journal of Pediatrics, 2022
- Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic reviewDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2022
- Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO studyDiabetologia, 2020
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Impaired Primary Immune Response in Type-1 Diabetes: Results from a Controlled Vaccination StudyClinical Immunology, 2002